Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study(†)

We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCβ] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Butowski, Nicholas, Chang, Susan M., Lamborn, Kathleen R., Polley, Mei Yin, Parvataneni, R., Hristova-Kazmierski, Maria, Musib, Luna, Nicol, Steven J., Thornton, Donald E., Prados, Michael D.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2010
Sujets:
Clinical Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940647/
https://ncbi.nlm.nih.gov/pubmed/20156802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop070
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires